Predicting Gout Flares in People Starting Allopurinol Using the Start-Low Go-Slow Dose Escalation Strategy

Area of Science:

• Rheumatology
• Clinical Pharmacology

Background:

• Gout flares are common when initiating urate-lowering therapy.
• The "start-low go-slow" allopurinol strategy aims to minimize flares.
• Predictors of flares during this initiation phase require further elucidation.

Purpose of the Study:

• To identify predictors of gout flares during allopurinol initiation using a "start-low go-slow" approach.
• To inform targeted anti-inflammatory prophylaxis strategies.

Main Methods:

• Post hoc analysis of a 12-month randomized controlled trial.
• Participants received colchicine or placebo for the first six months.
• Multivariate logistic regression identified flare predictors.

Main Results:

• Flare in the month before starting allopurinol and a 100 mg starting dose predicted early flares.
• Prior colchicine use, recent flares, and elevated serum urate at six months predicted later flares.

Conclusions:

• Targeted prophylaxis may benefit patients with recent flares starting 100 mg allopurinol.
• Extended prophylaxis might be needed for those experiencing flares despite initial treatment.